WallStSmart

Boston Scientific Corp (BSX)vsPerspective Therapeutics Inc. (CATX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 5133396% more annual revenue ($21.00B vs $409,000). BSX leads profitability with a 17.5% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 72/100 (B).

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 6.0Quality: 5.5
Piotroski: 5/9Altman Z: 1.78

CATX

Avoid

29

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -0.43
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXOvervalued (-14.4%)

Margin of Safety

-14.4%

Fair Value

$39.06

Current Price

$44.12

$5.05 premium

UndervaluedFair: $39.06Overvalued

Intrinsic value data unavailable for CATX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX5 strengths · Avg: 8.2/10
Market CapQuality
$64.66B9/10

Large-cap with strong market position

PEG RatioValuation
0.638/10

Growing faster than its price suggests

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

CATX2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

CATX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$285.38M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Price/Book. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.63 suggests the stock is reasonably priced for its growth.

Bull Case : CATX

The strongest argument for CATX centers on Price/Book, Debt/Equity.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : CATX

The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

BSX profiles as a mature stock while CATX is a value play — different risk/reward profiles.

CATX carries more volatility with a beta of 1.80 — expect wider price swings.

BSX is growing revenue faster at 7.5% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 29/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Perspective Therapeutics Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.

Visit Website →

Want to dig deeper into these stocks?